Form 8-K - Current report:
SEC Accession No. 0001641489-24-000010
Filing Date
2024-03-13
Accepted
2024-03-13 07:51:55
Documents
16
Period of Report
2024-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20240313.htm   iXBRL 8-K 25449
2 EX-99.1 vtvt-20231231xexx991pressr.htm EX-99.1 98944
6 GRAHPIC ex991.jpg GRAPHIC 6938
  Complete submission text file 0001641489-24-000010.txt   267942

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20240313.xsd EX-101.SCH 1913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20240313_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20240313_pre.xml EX-101.PRE 12516
18 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20240313_htm.xml XML 2829
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

EIN.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 24744602
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)